Skip to content

Performance Proof of Product Developed to Detect Abnormal Vaginal pH

Performance Proof of The Norma-Sense Gen 3 - Wearing Study

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01542606
Enrollment
0
Registered
2012-03-02
Start date
2019-03-31
Completion date
2019-12-31
Last updated
2019-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vaginal Infection

Keywords

PH, SCREENING, EARLY WARNING, VAGINAL HEALTH, VAGINAL SECRETION, VAGINAL PH

Brief summary

This study was designed to validate the color appearance on the NORMA-SENSE gen 3 when comes into contact with vaginal secretions having an elevated pH level

Detailed description

This study was designed to validate the color appearance on the NORMA-SENSE gen 3. The NORMA-SENSE gen 3 changes color when worn by the user and comes into contact with vaginal secretions having an elevated pH level, without false positives due to urine remains or incontinence. The study will also asses the physical comfort in using NORMA-SENSE gen 3 and the result reading clarity which includes the ability to visualize and interpret the NORMA-SENSE gen 3 results.

Interventions

The NORMA-SENSE gen 3 polymer matrix is stained by blue or green color on a pale yellow background when the pH level of the fluid in contact with it is greater than the cutoff value, and the user can consider any stain of color, which is different from the original background, as a positive result of the test.

Sponsors

Common Sense
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

1. Women, age 18 years or greater with or without symptoms of vaginal infection. 2. Subject is ready to sign the informed consent form.

Exclusion criteria

1. Subject is unable or unwilling to cooperate with study procedures. 2. Subject is currently participating in another clinical study. 3. Subject suffers from vaginal bleeding or is menstruating. 4. Subject that have had sexual relations within the last 12 hours. 5. Subject that applied local antiseptic or antibiotic or vaginal treatment within the last 3 days. 6. Subject that applied vaginal douching within 12 hours prior to the visit at the clinic.

Design outcomes

Primary

MeasureTime frameDescription
color status of the NORMA-SENSE gen 3 and the pH measurement.3 daysagreement between the color status of the NORMA-SENSE gen 3 as reported by the subject after using the panty liners, and the pH measurement with Nitrazine paper.

Secondary

MeasureTime frameDescription
physical comfort in using NORMA-SENSE gen 3 and the result reading clarity3 daysthe patient report regarding physical comfort in using NORMA-SENSE gen 3 and the result reading clarity including the ability to visualize and interpret the NORMA-SENSE gen 3 results.

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026